FGFR1 (fibroblast growth factor receptor 1) regulates many key cellular responses including proliferation, migration and differentiation through activation of signaling pathways. Irregularities in FGFR1 signaling have been implicated in several pathological conditions, including human cancer. In order to discover novel regulators of FGFR1 signaling, we performed yeast twohybrid screens and identified RSK2 (p90 ribosomal S6 kinase 2) as a potential FGFR1 interaction partner. RSK2 belongs to the family of serine/threonine kinases that are activated through the Ras-MAPK signal transduction pathway. Both in vitro and in vivo experiments confirmed the interaction and we show that phosphorylated RSK2 binds to and phosphorylates serine 789 in the C-terminal tail of FGFR1. Inhibition of RSK2 activity led to prolonged tyrosine transphosphorylation of FGFR1. Furthermore, prevention of FGFR1 phosphorylation by inhibition of RSK2 activity or mutation of serine 789 to alanine reduced FGFR1 endocytosis and ubiquitination explaining mechanistically the prolonged signaling activity. We propose a novel regulatory mechanism whereby activated RSK2 directly interacts with and phosphorylates FGFR1, thereby modulating receptor signaling through regulation of endocytosis.
INTRODUCTION
To maintain cellular homeostasis, cells receive signals through their cell surface receptors. One class of such receptors is the fibroblast growth factor receptor (FGFR) family, which belongs to the receptor tyrosine kinases. FGFR1 is one of the four FGFRs that binds and is activated by members of the fibroblast growth factor (FGF) family. 1 FGF binding leads to receptor dimerization and activation of the intrinsic kinase domain followed by transphosphorylation of several tyrosine residues in the intracellular part of the receptor. The signaling via FGFRs is then mediated by direct recruitment and phosphorylation of downstream signaling proteins and activation of multiple signal transduction pathways including Ras-MAPK, PI3K-AKT and PLCg-PKC. 2 FGFR1 signaling mediates diverse cellular responses such as cell survival, proliferation, differentiation and migration.
FGFR1 activity is tightly regulated to prevent excess signaling that could lead to inappropriate cellular responses. Irregularities in FGFR1-mediated signaling have been implicated in several pathological conditions including development and progression of human cancer. [3] [4] [5] In particular, amplification of the FGFR1 gene occurs frequently in certain types of cancer such as lung cancer and breast cancer and is often associated with poor prognosis and invasive disease. [6] [7] [8] Several ways to ensure accurate signaling from active receptors have evolved. Once activated, receptors can be removed from the cell surface by endocytosis. 9 The endocytosed receptor can then be degraded in lysosomes, leading to attenuation of the signaling. FGFR1 signaling can also be regulated through feedback mechanisms involving proteins such as MKP3 (MAPK phosphatase 3), SEF (Similar expression to FGF) and Sprouty 1/2. 10, 11 Furthermore, activated ERKs can directly phosphorylate serines and threonines in upstream signaling molecules such as FRS2 (FGF receptor substrate 2). ERKmediated phosphorylation of threonine residues in FRS2 leads to reduced FRS2 tyrosine phosphorylation and attenuation of signaling. 12 Recently, we have shown that ERKs can also bind directly to FGFR1 and phosphorylate FGFR1 at serine 777 in its C-terminal tail. 13 Phosphorylation of serine 777 in FGFR1 results in reduced tyrosine phosphorylation and thus decreased FGFR1 signaling.
Here, we have identified the serine/threonine kinase RSK2 (p90 ribosomal S6 kinase 2) as a binding partner of FGFR1. RSK2 is a serine/threonine kinase that acts as a downstream effector of the Ras-MAPK signaling cascade.
14 RSK2 possesses two kinase domains, the C-terminal kinase domain and the N-terminal serine/threonine kinase domain (NTKD). Active ERK1/2 phosphorylate and activate the C-terminal kinase domain, which in turn autophosphorylates RSK2 in its linker region creating a docking-site for PDK1, a constitutively active serine/ threonine kinase. PDK1 phosphorylates a specific serine in the NTKD resulting in complete RSK activation. The active NTKD in RSK can then phosphorylate multiple downstream substrates to regulate processes such as cell growth, proliferation, survival and motility. Interestingly, we found that active RSK2 phosphorylates FGFR1 at serine 789 and inhibition of RSK2 leads to increased tyrosine phosphorylation of the receptor and reduces FGF1-induced receptor ubiquitination and endocytosis. We propose a novel feedback mechanism for FGFR1 activity through active RSK2.
RESULTS

Identification of RSK2 as an FGFR1 interacting protein
To identify novel potential FGFR1 interaction partners, we performed three yeast two-hybrid screens. In one screen, the whole intracellular part of FGFR1 (amino acids 398-822) was used as bait (bait 1) (Figure 1a ). Since ectopic overexpression of FGFR1 can cause activation and autophosphorylation of the receptor, we also performed another experiment, where we used the intracellular part of FGFR1 with a K514R mutation (bait 2). FGFR1 K514R is a kinase-dead mutant and prevents autophosphorylation of FGFR1. The third screen was performed with a fragment consisting of the 60 last amino acids of the C-terminal part of FGFR1 as bait (bait 3) (Figure 1a ). The RSK2 protein was identified as an FGFR1 interaction partner protein with high confidence score in all three screens (Supplementary Figure S1-3) . RSK2 was shown to bind to the intracellular part of the receptor, regardless of the K514R mutation, as well as to the C-terminal part of FGFR1 (last 60 amino acids). The minimal interacting domain or selected interacting domain in RSK2 was identified to the NTKD of RSK2 (Figure 1a ).
To confirm the results from the yeast two hybrid-screens, we first tested whether FGFR1 could interact with endogenous RSK2 in mammalian cells. U2OS-R1, a human osteosarcoma cell line stably transfected with full length FGFR1, were left untreated or treated with FGF1 for 15 min. As seen in Figure 1b , RSK2 was coimmunoprecipitated with FGFR1 (left panel). Interestingly, the interaction between the proteins was highly increased upon stimulation of cells with FGF1. Conversely, FGFR1 was also coimmunoprecipitated with RSK2 ( Figure 1b, right panel) . Neither FGFR1 nor RSK2 were co-immunoprecipitated with the control IgG. These data confirm that RSK2 is an interaction partner of FGFR1 in mammalian cells.
From the yeast two-hybrid screen it was evident that RSK2 can interact with the C-terminal 60 amino acids of FGFR1, indicating that the RSK2 binding site is restricted to the C-terminal part of the receptor. Further evidence for this was obtained from GST pulldown experiments of endogenous RSK2 from BJ fibroblasts, using a recombinant GST-tagged C-terminal part of FGFR1, Ct-FGFR1 (68 last amino acids in FGFR1). Recently, we have shown that serine 777 in the C-terminal part of FGFR1 is important for IB: RSK2  IB: RSK2   IB: FGFR1   kDa   150  150   kDa  +  +  +  +  +  -----S777D  WT  GST  WT  GST   RSK2   +  +  +  +  FGF1  --kDa  FGF1 -- Protein complexes were pulled down using glutathione-conjugated sepharose resin and analyzed by western blotting with indicated antibodies.
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binding of ERK1 and 2 to FGFR1. 13 Therefore, binding to GSTtagged C-terminal part of FGFR1 mutant S777A and S777D was also examined. Serum-starved BJ cells were left untreated or treated with FGF1 for 15 min. After cell lysis, 3 mg of the FGFR1 fusion proteins were added to the lysates and next, GST-fusions and its associated proteins were pulled down, separated by SDS-PAGE and analyzed by western blotting (Figure 1c ). As expected, RSK2 was able to bind to the C-terminal part of FGFR1. Mutation of serine 777 in FGFR1 did not influence binding of RSK2 to FGFR1, indicating that RSK2 and ERKs bind to different sites in the C-terminal part of FGFR1. Interestingly, binding was only observed in the presence of FGF1 stimulation.
Phosphorylated RSK2 binds to the C-terminal part of FGFR1 Stimulation of U2OS-R1 cells with FGF1 leads to transphosphorylation of the kinase domain of the receptor as well as to activation of the ERK kinase pathway and hence activation of their substrates such as RSK2. 15 To further test if the association between FGFR1 and RSK2 depends on phosphorylation of FGFR1 or RSK2, we stimulated cells with EGF or 10% serum. Both EGF and serum can activate RSK2 but they do not induce tyrosine transphosphorylation of FGFR1.
Serum-starved U2OS-R1 cells were treated with FGF1, EGF or 10% serum in the presence of selective inhibitors (as indicated). The cells were then lysed and co-immunoprecipitation between RSK2 and FGFR1 was analyzed by SDS-PAGE and immunoblotting Cells were also pretreated with BI-D1870, a specific RSK inhibitor, which inhibits downstream RSK activity although RSK itself is phosphorylated. 16 Efficiency of the inhibitor was tested by immunoblotting using an antibody against the phospho-form of the RSK substrate, LKB1 (Figure 2a , lane 9 and 10). Treatment of cells with BI-D1870 did neither affect the FGF1-and EGF-induced activation of ERKs nor phosphorylation of RSK2 at S227 (anti-RSK1 S221/RSK2 S227 antibody) but phosphorylation of LKB1 was not observed. However, treatment with BI-D1870 did not disturb the interaction between FGFR1 and RSK2. In all the conditions tested, the phosphorylation status of ERK1/2 and subsequent RSK2 phosphorylation were crucial for RSK2 binding to FGFR1, indicating that the association between RSK2 and FGFR1 depends on RSK2 phosphorylation status rather than RSK2 activity.
Interestingly, a detailed analysis of the time course of the phosphorylation events of FGFR1, ERK1/2 and RSK2 upon FGF1 treatment revealed that these events occur in a successive manner. As shown in Figure 2b , FGFR1 was phosphorylated immediately after addition of FGF1 while ERK1/2 were phosphorylated several minutes after addition of FGF1 and was then followed by phosphorylation of RSK2. This is in accordance with our data in Figure 2a and favors a model where FGF1 induces activation of ERK1/2 leading to ERK1/2-mediated phosphorylation of RSK2 which are then able to bind to the receptor. Thus, binding of RSK2 to FGFR1 is somewhat delayed compared to activation of the receptor.
Serine 789, 790 and 794 in the C-terminal part of FGFR1 are involved in binding of RSK2 RSK2 phosphorylates multiple substrates at serine/threonine residues within a consensus sequence, R-X-R-X-X-pS/T or R-R-XpS/T. 14, 17 The C-terminal part of FGFR1 includes a motif which resembles that of RSK2 substrates ( 784 RSSTCS 789 , Figure 3a) . Interestingly, the serine residue at position 789 in FGFR1 is conserved across vertebrate species in all four FGFRs. 13 First, we examined whether amino acids in proximity to this site were necessary for the binding of RSK2 to FGFR1. We started with the following double mutants in which serine (S) or threonine (T) residues were substituted for alanine (A) in order to prevent phosphorylation or aspartic acid (D) residues in order to mimic phosphorylation: FGFR1-S779A/T783A, FGFR1-S779D/ T783D, FGFR1-S785A/S786A; FGFR1-S785D/S786D, FGFR1-S789A/ S790A, FGFR1-S789D/S790D, FGFR1-S794A/S797A, FGFR1-S794D/ S797D. Cells were transiently transfected for 24 h with one of the FGFR1 double mutants, serum starved for 6 h and then stimulated with FGF1 for 15 min. Lysates were subjected to immunoprecipitation with anti-FGFR1 antibody followed by immunoblotting with anti-RSK2 antibody (Figure 3b) . Interestingly, binding of RSK2 to FGFR1 S789A/S790A, FGFR1 S789D/S790D and S794A/S797A mutants was significantly reduced. In the case of S779D/T783D, apparently little RSK2 was immunoprecipitated with FGFR1. However, this could be due to the low expression level of FGFR1 S779D/T783D in transiently-transfected cells (Figure 3b) .
In U2OS cells stably transfected with FGFR1, the association between RSK2 and FGFR1 was induced by FGF1 stimulation and activation of RSK2 (Figure 2a ). However, in cells transiently transfected with FGFR1 wild-type, we observed an association between RSK2 and FGFR1 even in the absence of FGF1. Concomitantly, we also observed that ERKs were active in the absence of FGF1 (Figures 3b and c) . This is most likely due to ligand-independent dimerization and transphosphorylation induced by over-expression of the receptor.
To evaluate which of the particular serine or threonine residues of the selected double mutants were responsible for the disruption of RSK2 binding to FGFR1, we narrowed down from the double mutants to single ones: S779D, T783D, S789A, S789D, S790A, S790D, S794A, S797A, and binding of RSK2 was assessed as described above. Substitution of S779 or T783 to aspartic acid did not reduce the binding of RSK2 to FGFR1, indicating that the effect described for the double mutant S779D/T783D is most likely due to its low expression level as discussed above. However, independent substitution of S789, S790 or S794 to alanine severely reduced the binding of RSK2 to FGFR1 (Figure 3c ). Substitution of S789 or S790 to aspartic acid also reduced the binding of RSK2 to FGFR1 compared to FGFR1 wild-type but to a lesser extent than the alanine mutants. Taken together, the data show that binding of RSK2 to FGFR1 is impaired in these FGFR1 mutants: S789A, S789D, S790A, S790D and S794A.
FGFR1 is directly phosphorylated by RSK2
To test if RSK2 itself can phosphorylate FGFR1, we performed in vitro phosphorylation assays. Purified active RSK2 kinase was mixed with recombinant GST-tagged C-terminal part of FGFR1 WT (Ct-FGFR1 WT) or GST alone in the presence of [g-33 P] ATP. GSTtagged C-terminal parts of FGFR1 mutant S777A and S777D were also included in order to test whether RSK2 phosphorylation of FGFR1 depends on S777 phosphorylation status.
Phosphorylation of the recombinant FGFR1 proteins was observed in all cases while no phosphorylation of the GST protein alone was observed (Figure 4a ). Moreover, phosphorylation of the wild-type Ct-FGFR1 was significantly decreased in a dosedependent manner after addition of increasing concentrations of BI-D1870, a specific RSK inhibitor (Figure 4b) . Also, an inactive form of RSK2 was not able to phosphorylate Ct-FGFR1 (Figure 4b , last lane). These data indicate that RSK2 can directly phosphorylate the C-terminal part of FGFR1.
To identify the RSK2 phosphorylation site within FGFR1, Ct-FGFR1 subjected to in vitro phosphorylation by active, recombinant RSK2 was analyzed by mass spectrometry (MS). The performed MS analysis did not indicate unambiguously the phosphorylation site within Ct-FGFR1, but pointed out the region of the receptor most likely to be phosphorylated by RSK2 (data not shown). Therefore, we applied a different approach and analyzed by MS and MS/MS three synthetic peptides covering the whole sequence with potential phosphorylation sites (serines and threonines) in the C-terminal part of FGFR1 (Figure 4c ). Peptide 2 and 3 contain the putative RSK2 phosphorylation motif ( 784 RSSTCS 789 ). In the presence of RSK2, we observed an increase in mass of peptide 2 by 75.97 Da, in contrast to the control experiment performed in the absence of RSK2. The change in the peptide mass, however, was about 4 Da lower than theoretical mass change occurring upon a single phosphorylation event The association between RSK2 and FGFR1 depends on RSK2 phosphorylation. (a) Serum starved U2OS-R1 cells were pretreated, as indicated, for 30 min with 100 nM PD173074, 20 mM U0126 or 10 mM BI-D1870 and then treated for 15 min with 100 ng/ml FGF1 or EGF or 10% serum. Cell lysates were then subjected to immunoprecipitation reactions using anti-FGFR1 antibodies followed by SDS-PAGE and western blotting with indicated antibodies. (b) Serum-starved U2OS-R1 cells were stimulated with 100 ng/ml FGF1 and 10 U/ml heparin for indicated periods of time. The cells were then lysed, and the lysates were analyzed by SDS-PAGE and western blotting with indicated antibodies. Western blots were quantified and the bands corresponding to the phosphorylated proteins were normalized to the bands corresponding to total ERK1/2 and presented in the graphs as a fraction of their maximal response. In the case of p-RSK1/2 the background band at time point zero was subtracted before normalizing to the total ERK1/2 levels. The graph represents the mean±standard deviation of three independent experiments.
(79.97 Da). To determine the phosphorylation site and confirm its specificity, MS/MS analysis of this peptide was performed. The results revealed that a single phosphorylation occurs specifically on serine 789 (S789) in peptide 2 (Figure 4c, table to the right) . Surprisingly, two other modifications, oxidation of cysteine 788 and dehydration of threonine 787 and serine 790, were found to be present simultaneously with the S789 phosphorylation. When all these modifications are considered, the experimental mass of peptide 2 subjected to in vitro phosphorylation by RSK2 is in accordance with the calculated mass for the modified peptide. MS/MS analysis of peptide 3 upon in vitro phosphorylation by RSK2 showed exactly the same modifications as found for peptide 2 (Supplementary Figure S4a) demonstrating that the observed events are independent of the peptide length and range. We also performed MS analysis of peptide 1. Peptide 1 is rich in serines and contains the serine 777, which we previously identified as a phosphorylation site for ERK1/2. 13 As shown in Supplementary Figure S4b , peptide 1 was not phosphorylated by RSK2. This confirms the specificity of the phosphorylation and points to a particular and independent role of selected serines in the C-terminal tail of FGFR1.
To determine whether S789 phosphorylation by RSK2 also occurs in the full length human FGFR1 in intact cells, we obtained a phospho-specific polyclonal rabbit antibody against serine 789 in FGFR1 (p-S789-FGFR1). Unfortunately, the antibody recognized several proteins in lysates from U2OS-R1 cells stimulated with FGF1, EGF or 10% serum (data not shown). This might be due to shared RSK phosphorylation motif by other AGC family members of protein kinases.
14 Therefore, the phosphorylation status of S789 was examined by immunoblotting using the p-S789-FGFR1 antibody after immunoprecipitation of the receptor with anti-FGFR1 antibody. Moreover, to avoid possible autophosphorylation and constitutive activation of RSK2 by transient over-expression of FGFR1, we generated U2OS cells stably expressing FGFR1 S789A or FGFR1 S789D. Serum-starved U2OS-R1 WT, S789A or S789D cells were left untreated or treated with FGF1 or EGF before immunoprecipitation with anti-FGFR1 antibody, followed by immunoblotting using the p-S789-FGFR1 antibody. The band corresponding to phosphorylated S789 in FGFR1 was present in lysates from U2OS-R1 cells but hardly detectable in the S789 mutants ( Figure 4d ) and was increased upon FGF1 and EGF stimulation compared to untreated cells. Upon longer exposures, bands were also observed in lysates from U2OS-R1 mutant cells (data not shown) indicating that the antibody might have some reactivity against the un-phosphorylated form. The p-S789-FGFR1 antibody did not recognize FGFR1 in U2OS-R1 S789D cells indicating that this mutant might not act in a phospho-mimetic manner.
To further confirm that RSK2 can phosphorylate FGFR1 at S789 in living cells, serum-starved U2OS-R1 cells were left untreated U0126 - Serum-starved U2OS (control), U2OS-R1, U2OS-R1 S789A or U2OS-R1 S789D cells were left untreated or treated with FGF1 or EGF for 15 min (as indicated). The cells were then lysed and the lysates were subjected to immunoprecipitation reactions using anti-FGFR1 antibodies followed by SDS-PAGE and western blotting with indicated antibodies. (e) FGFR1 is phosphorylated at serine 789 by RSK2 in vivo. Serum-starved U2OS-R1 cells were treated with 10 mM BI-D1870 or 20 mM U0126 MEK1/2 inhibitor for 30 min prior to FGF1 or EGF treatment (as indicated). The cells were then lysed and the lysates were subjected to immunoprecipitation reactions using anti-FGFR1 antibodies followed by SDS-PAGE and western blotting with indicated antibodies.
showed that S777 in FGFR1 is phosphorylated by ERKs. Immunoblotting using a specific antibody against phospho-serine 777 in FGFR1 (p-S777-FGFR1) revealed that U0126 treatment efficiently inhibited S777 phosphorylation while BI-D1870 had no effect on S777 phosphorylation. Taken together, both the in vitro and the in vivo data suggest that active RSK2 phosphorylates the C-terminal part of FGFR1, specifically at serine 789.
Tyrosine phosphorylation of FGFR1 is enhanced by blocking RSK2 activity or knockdown of RSK2 by siRNA To test if RSK activity regulates FGFR1 signaling, we analyzed the effect of inhibition of RSK on FGFR1 tyrosine phosphorylation using specific RSK inhibitors. Serum-starved U2OS-R1 cells were pretreated for 30 min with 10 mM BI-D1870 or 100 mM SL 0101-1, two highly specific inhibitors of RSK, both acting as ATPcompetitors, 16, 18 prior to stimulation with FGF1 for the indicated times. The experiment was performed in the presence of Brefeldin A to prevent interference of newly synthesized FGFR1 transported to the plasma membrane as shown previously. 15 The activity of FGFR1 was examined by immunoblotting using a phosphotyrosine-specific antibody against FGFR (p-Tyr-FGFR1). The band corresponding to tyrosine-phosphorylated FGFR1 as well as that corresponding to the fully glycosylated form of FGFR1 was more persistent over time in cells treated with the RSK inhibitors than in untreated cells (Figures 5a and b) . Quantifications of three independent experiments revealed that treatment of cells with BI-D1870 or SL 0101-1 prolonged the tyrosine phosphorylation of FGFR1.
FGF1-stimulation of cells transfected with siRNA oligos targeting RSK2 also led to enhanced tyrosine phosphorylation of FGFR1 compared to control cells (Figure 5c ). Although a clear effect was observed, the effect was not as pronounced after longer times with FGF1 stimulation as in the case of treatment with inhibitors of RSK2. We suspect that this might be due to low levels of residual RSK2. Differently from the acute inhibition caused by treatment with BI-D1870 and SL 0101-1, the knockdown of RSK2 using siRNA oligos causes lower levels of RSK2 over longer time intervals and led to higher levels of FGFR1 already at time point zero.
Taken together, these data show that inhibition of RSK activity or depletion of endogenous RSK2 leads to enhanced tyrosinephosphorylation of FGFR1.
FGF-induced ubiquitination of FGFR1 is reduced by inhibition of RSK activity Since defects in receptor-mediated endocytosis might lead to prolonged tyrosine-phosphorylation, we next examined whether Figure 5 . Disruption of RSK2 leads to prolonged FGFR1 tyrosine phosphorylation. (a and b) Serum-starved U2OS-R1 cells were pretreated with 10 mM BI-D1870 (a) or 100 mM SL 0101-1 (b) in the presence of 2 mg/ml Brefeldin A. Next, the cells were treated with 100 ng/ml FGF1 for indicated periods of time. The cells were then lysed and lysates were analyzed by SDS-PAGE and western blotting with indicated antibodies. Western blots were quantified and the bands corresponding to tyrosine phosphorylated FGFR1 were normalized to GAPDH. The amount of tyrosine phosphorylated FGFR1 is presented as percentages of that in cells stimulated with FGF1 for 15 min in the absence of inhibitor. The graph represents the mean ± standard deviation of three independent experiments. (c) Non-targeting siRNA (scr) or RSK2-specific siRNA were transfected into U2OS-R1 cells. 48-72 h after transfection cells were serum-starved and pretreated for 30 min with Brefeldin A prior to stimulation with FGF1 for indicated periods of time. The cells were then lysed and lysates were analyzed by SDS-PAGE and western blotting with indicated antibodies. Western blots were quantified and the bands corresponding to tyrosine-phosphorylated FGFR1 were normalized to GAPDH. The amount of tyrosine-phosphorylated FGFR1 is presented as percentages of that in scr-transfected cells stimulated with FGF1 for 15 min. The histogram represents the mean ± standard deviation of three independent experiments.
FGFR1-ubiquitination was affected by inhibition of RSK activity.
Receptor ubiquitination is one of the main regulating events of the endocytic processes. 19 To test if RSK activity can regulate FGFR1 ubiquitination, we examined FGF1-induced ubiquitination of FGFR1 in cells pretreated with the RSK inhibitor, BI-D1870. Ubiquitination of FGFR1 was examined by immunoblotting of FGFR1 immunoprecipitates and detected as a smear of bands migrating more slowly than the non-ubiquitinated receptor (Figure 6a) . Pretreatment of cells with the RSK inhibitor reduced the level of FGF1-induced FGFR1-ubiquitination substantially. Quantification of three independent experiments showed that the level of FGFR1-ubiquitination increased upon FGF1 stimulation, while in FGF-stimulated cells pretreated with the RSK2 inhibitor, the level of FGFR1-ubiquitination was significantly decreased.
The ubiquitination of FGFR1 was also reduced in U2OS cells stably expressing FGFR1 S789A compared to wild-type FGFR1 expressing cells (Figure 6b ). These results show that FGFR1 is less ubiquitinated when the RSK2 kinase is inhibited or when FGFR1 is prevented from being phosphorylated on S789.
Endocytosis of FGFR1 is reduced by inhibition of RSK activity Since inhibition of RSK2 activity resulted in prolonged FGFR1 signaling combined with a reduced level of FGFR1-ubiquitination, we hypothesized that phosphorylation of serine 789 in FGFR1 by RSK2 might play a role in FGFR1 endocytosis. To test this, the kinetics of endocytosis of wild-type FGFR1 in the presence or absence of the RSK2 inhibitor (BI-D1870) were examined. U2OS-R1 cells treated or not with the inhibitor were incubated with 125 I-FGF1 or 125 I-FGF2 for different periods of time and the rate of internalization was measured as the ratio of internalized to surface-bound 125 I-FGF and plotted as function of time. Interestingly, treating cells with BI-D1870 significantly decreased the rate of endocytosis (Figure 7a ). In addition, we performed the same experiments in the presence of the specific MEK inhibitor, U0126. Also, in this case, the rate of endocytosis was significantly reduced in U2OS-R1 cells treated with the inhibitor (Figure 7b) . We have previously reported that FGFR1 can be phosphorylated on serine 777 by ERKs or by p38. 13, 20 Phosphorylation of serine 777 by ERKs plays a role in FGFR1 signaling, as we recently reported that substitution of serine 777 in FGFR1 with alanine led to increased FGFR1 signaling. 13 To rule out whether phosphorylation of serine 777 also influences FGFR1 endocytosis, we examined the rate of endocytosis in U2OS cells transiently transfected with FGFR1 wildtype or FGFR1 S777A mutant in the presence or absence of U0126, the specific MEK inhibitor. As seen in Figure 7c , U2OS cells expressing either FGFR1 wild-type or FGFR1 S777A mutant were internalized at a similar rate. Treatment with MEK inhibitor reduced the rate of internalization to a similar degree in both cases. The results indicate that although activation of MEK/ERK is essential for proper endocytosis of FGFR1, phosphorylation of serine 777 is not required. In addition, we also examined the rate of endocytosis upon treatment of U2OS-R1 cells with SB203580, a specific p38 inhibitor. Treatment with p38 inhibitor did not alter the rate of endocytosis (Figure 7d ). Taken together, the data indicate that phosphorylation of FGFR1 by RSK2 rather than ERK is the crucial event regulating FGFR1 endocytosis.
Next, we wanted to examine whether the binding of RSK2 to FGFR1 and the phosphorylation status of serine 789 in FGFR1 play a role in FGFR1 endocytosis. U2OS-R1 wild-type or U2OS-R1 S789A cells were incubated with 125 I-FGF2 for different periods of time and the rate of internalization was measured as the ratio of internalized to surface-bound 125 I-FGF2. Cells expressing the serine 789 FGFR1 mutant internalized FGF2 at a slower rate than wild-type expressing cells (Figure 7e ).
To further investigate the effect of RSK2 on FGFR1 endocytosis, we used confocal microscopy to study FGF1 internalization. Starved U2OS-R1 cells were stimulated with DyLight 549-labeled FGF1 (DL-FGF1) for 20 min, washed with high salt, low pH buffer (HSLP buffer), fixed and examined by confocal microscopy. Washing with HSLP buffer removes DL-FGF1 remaining at the cell surface and was included to ensure that the observed DL-FGF1 structures represent internalized FGF1. The images were captured with identical settings to be able to directly compare and quantify the DL-FGF1 intensity representing endocytosed FGF1. While DL-FGF1 was readily observed in control cells, hardly any DL-FGF1 was observed within U2OS-R1 cells pretreated with RSK or MEK1/2 inhibitors (Figure 7f ). To verify that the inhibitortreatment did not alter the amount of receptors at the cell surface, we compared binding of FGF1 to the cell surface in treated and untreated cells, and no difference was observed (Supplementary Figure S5a) . Next, we examined the uptake of DL-FGF1 in U2OS cells stably expressing FGFR1 S789A and wild-type FGFR1 expressing cells. Indeed, less DL-FGF1 was observed within U2OS-R1 S789A cells compared to U2OS-R1 cells (Figure 7h ). The amount of FGFR1 at the cell surface was similar in U2OS-R1 and U2OS-R1 S789A cells (Supplementary Figure S5b) . Quantification of the intensity of the internalized DL-FGF1 revealed that treatment with RSK2 or MEK1/2 inhibitors reduced the amount of internalized FGF1 to 3-5% of that in untreated cells (Figure 7g) . In U2OS-R1 S789A cells, the amount of internalized DL-FGF1 was reduced to approximately 20% of that in U2OS-R1 cells (Figure 7i ). The data are in accordance with the findings above and suggest that loss of RSK2 activity leads to defective internalization of the activated receptor. (a) Serum-starved U2OS-R1 cells were pretreated with 10 mM BI-D1870 RSK2 kinase inhibitor for 30 min prior to FGF1 (100 ng/ ml) treatment for 15 min. Cells were lysed at 95 1C for 5 min in 1% SDS in PBS. Equal amounts of lysate and 2 Â IP-buffer were mixed and subjected to immunoprecipitation reactions using anti-FGFR1 antibodies followed by SDS-PAGE and western blotting with indicated antibodies. Western blots were quantified and the bands corresponding to ubiquitinated FGFR1 (Ub) were normalized to total FGFR1. The histogram represents the mean ± standard deviation of three independent experiments. *Po0.05, **Po0.01. (b) Serumstarved U2OS-R1 and U2OS-R1 S789A cells were stimulated with 100 ng/ml FGF1 for 15 min. Cells were lysed at 95 1C for 5 min in 1% SDS in PBS. Equal amounts of lysate and 2 Â IP-buffer were mixed and subjected to immunoprecipitation reactions using anti-FGFR1 antibodies followed by SDS-PAGE and western blotting with indicated antibodies. Western blots were quantified and the bands corresponding to ubiquitinated FGFR1 (Ub) were normalized to total FGFR1. The amount of ubiquitinated receptor is presented relative to untreated cells. The histogram represents the mean±standard deviation of three independent experiments. a.u., arbitrary units. *Po0.05, **Po0.01, ***Po0.001.
We also examined the uptake of DL-FGF1 into EEA1 (early endosomal antigen)-positive endosomes 21 over time by performing a pulse-chase experiment. Starved U2OS-R1 cells were kept at 4 1C with DL-FGF1 to facilitate binding of the ligand to cell surface FGFR1. Excess ligand was then removed by washing, and the cells were immediately transferred to 37 1C for the indicated periods of time. The cells were then fixed, stained with anti-EEA1 antibody and examined by confocal microscopy. The images were captured with adjustment of the intensity in such a way that the whole intensity range for DL-FGF1 was used in each image. This was performed in order to quantify the fraction of EEA1 overlapping DL-FGF1 according to Mender's coefficient. When inhibitors were used, the cells were pretreated for 1 h prior to addition of 125 I-FGF, and the inhibitor was kept throughout the experiment. Internalized and surface-bound 125 I-FGF were separated as described in Materials and methods and the ratio was plotted as function of time. Graphs represent means ± standard deviation of 2 (a), 5 (b) or 3 (d) independent experiments, each performed in triplicate. (e) Serum-starved U2OS-R1 and U2OS-R1 S789A cells grown on gelatinized plates were incubated with 20 ng/ml 125 I-FGF2 for indicated periods of time. Internalized and surface-bound 125 I-FGF were separated as described in Materials and methods, and the ratio was plotted as function of time. Graphs represent means±standard deviation of 3 independent experiments, each performed in triplicate. (f ) Serum-starved U2OS-R1 cells, grown on coverslips were incubated with DyLight 549 labeled FGF1 (DL-FGF1) at 37 1C for 20 min. The cells were then washed with a high salt, low pH buffer to remove surface bound DL-FGF1 before fixation followed by staining with Hoechst and examination by confocal microscopy. Inhibitors were added as indicated. When inhibitors were used, the cells were pretreated for 1 h prior to addition of DL-FGF1, and the inhibitor was kept throughout the experiment. Scale bar, 5 mm. (g) The uptake of DL-FGF1 was measured as DL549 intensity in U2OS-R1 cell treated as described in (f). The mean intensity of DL549 in inhibitor-treated cells is presented in the histogram as the percentage of DL549 intensity in untreated cells. The histogram represents the means±s.e.m. of 3 independent experiments. In total, 223 cells were analyzed for control, 249 for BI-D1870 treatment and 174 for U0126 treatment. Confocal scanning was performed with identical settings. ***Po0.001 (h) Serum-starved U2OS-R1 and U2OS-R1 S789A cells, grown on coverslips were incubated with (DL-FGF1) at 37 1C for 20 min. The cells were then washed with a high salt, low pH buffer to remove surface bound DL-FGF1 before fixation followed by staining with Hoechst and examination by confocal microscopy. Scale bar, 5 mm. (i) The uptake of DL-FGF1 was measured as DL549 intensity in U2OS-R1 and U2OS-R1 S789A cells. The mean intensity of DL549 in U2OS-R1 S789A cells are presented in the histogram as the percentage of DL549 intensity in U2OS-R1 cells. The histogram represents the means±s.e.m. of 3 independent experiments. In total, 182 cells were analyzed for U2OS-R1 and 165 for U2OS-R1 S789A. Confocal scanning was performed with identical settings. ***Po0.001.
At time point 0, cell surface staining of DL-FGF1 could be observed in all cases (Figure 8 ). In cells treated with BI-D1870, the cellsurface staining was still visible after 10-15 min incubation at 37 1C, while in control cells the cell-surface staining had disappeared after 10 min at 37 1C (Figure 8a ). Moreover, using Manders' coefficient we calculated the fraction of EEA1 overlapping with DL-FGF1, and we observed that in control cells the overlap was significantly higher (Manders' coefficient ¼ B0.6 after 20 min of incubation at 37 1C) than in BI-D1870 treated cells (Manders' coefficient ¼ B0.3 after 20 min of incubation at 37 1C). In U2OS-R1 S789A cells, similar effects were observed although less pronounced (Figure 8b) . The cell surface staining was prolonged in cells expressing mutant FGFR1 compared to wildtype expressing cells, and the overlap between EEA1 and DL-FGF1 calculated using Manders' coefficients were lower at all time points in FGFR1 S789A expressing cells than in the wild-type expressing cells. The largest difference was observed after 10 min incubation at 37 1C.
Taken together, the data indicate that when RSK2 activity is inhibited or when S789 in FGFR1 is mutated, the endocytosis of FGFR1 is reduced. Clearly, phosphorylation of S789 in FGFR1 by RSK2 is important for proper FGFR1 endocytosis.
DISCUSSION
Accurate signaling from receptor tyrosine kinases is maintained through tight regulation by several mechanisms. Here, we propose a novel mechanism for regulation of signaling from the receptor tyrosine kinase, FGFR1. Activated RSK2, a serine/ threonine kinase in the MAPK signaling pathway, constitutes a negative feedback loop on FGFR1 by binding and phosphorylating FGFR1 in its intracellular tail at serine 789. Inhibition of RSK2 leads to enhanced FGFR1 phospho-tyrosine signaling and reduced FGFR1 ubiquitination and endocytosis ( Figure 9) .
Recently, we published that FGFR1 is phosphorylated by ERK1/2 at serine 777 in its C-terminal part. 13 This phosphorylation, similar to the RSK2-mediated phosphorylation of serine 789, influences the duration of FGFR1 tyrosine phosphorylation and thereby the signaling from the activated receptor. In contrast to RSK2-mediated phosphorylation of serine 789, ERK1/2 phosphorylation of serine 777 does not influence the rate of endocytosis of FGFR1. It is not clear how phosphorylation of serine 777 influences the tyrosine phosphorylation of FGFR1 but one possible explanation is that the phosphorylated serine 777 could act as a binding site for tyrosine phosphatases. Both serines are located in the unstructured C-terminal end of the receptor. Besides the well-described phosphorylation of tyrosine 766 which serves as a binding site for PLC-g, 22 little is known about the biological function of the serine-and threonine-rich, unordered C-terminal part of FGFR1. Here, we describe a functional role of the serines in the C-terminal part of FGFR1 in negatively regulating FGFR1 signaling.
Receptor-mediated endocytosis leads to clearance of the receptors from the cell surface and transport into early endosomes. We have previously reported that FGFR1 in early endosomes is efficiently sorted to degradation in lysosomes. 23 We have also reported that efficient sorting of FGFR1 to lysosomes depends on receptor-ubiquitination. An ubiquitination-deficient FGFR1 mutant escaped lysosomal targeting and was recycled back to the cell surface resulting in prolonged signaling. 15 Here, we demonstrate that upon RSK2 inactivation, FGF1-induced ubiquitination of FGFR1 is significantly reduced, receptor signaling is prolonged and endocytosis is impaired.
We have reported that ubiquitination-deficient FGFR1 mutants are internalized at a similar rate as the wild-type FGFR1, indicating that ubiquitination is not required for the initial step in the endocytic process. 15 Also, it is not entirely clear if the receptors become ubiquitinated at the cell surface or at later stages in the endocytic pathway or both. It is plausible that the reduced level of ubiquitination upon treatment with RSK2 inhibitors is an effect of the impaired endocytosis rather than the direct cause of impaired endocytosis. Alternatively, RSK2 activity might be required for proper receptor ubiquitination and for receptor-internalization by two different, disconnected mechanisms. It will be interesting to investigate whether phosphorylation of serine 789 in FGFR1 causes recruitment of molecules involved in endocytosis and ubiquitination and to what extent these events are overlapping and connected events or not.
Other signaling receptors, among them the epidermal growth factor receptor (EGFR) and the receptor for hepatocyte growth factor, c-Met, have also been reported to be phosphorylated at serine residues in its intracellular part resulting in negative regulation of receptor signaling. 24, 25 Interestingly, the phosphorylation of EGFR on serine residues, among these serine 1047 and serine 1048, is thought to be critical for EGFR desensitization through regulating receptor internalization and degradation. [25] [26] [27] Phosphorylation of serine 1047 and serine 1048 has also been implicated in EGFR ubiquitination as substituting these serine residues to alanines resulted in reduced EGFR ubiquitination. 25 Recently, it was shown that phosphorylation of serine 1047 and serine 1048 in EGFR reduces the binding affinity of the ubiquitin ligase c-Cbl to EGFR. 28 This is probably not the case for FGFR1. Firstly, Cbl has not been shown to bind directly to FGFR1 but rather indirectly via Grb2 and FRS2 29 and secondly, serine 789 in FGFR1 is not in proximity to consensus binding sequences ((N/D)XpY(S/T)XXP or DpYR) of Cbl. Recently, it was reported that the E3 ubiquitin ligase, Nedd4, binds to FGFR1 and mediates FGF1-induced FGFR1 ubiquitination. 30 However, Nedd4 was shown to bind to the juxtamembrane region of FGFR1 and is therefore unlikely to be affected by phosphorylation of S789. Phosphorylation of S789 in FGFR1 might be required to recruit additional protein complexes involved in receptor internalization and ubiquitination.
Upon treatment with RSK2 inhibitor, we observed a stronger effect on endocytosis of the receptor than in cells expressing the FGFR1 S789A mutant. The substitution of a serine residue for an alanine is not exactly the same as a dephosphorylation and as the serine side-chain is sterically larger than an alanine side chain, it is possible that structural changes may interfere. It is also possible that serines in proximity to serine 789 can be phosphorylated when serine 789 is substituted for an alanine and at least partially rescue the effect of lack of serine 789 phosphorylation. However, since RSK2 does not bind to FGFR1 S789A this is not very likely. Another possibility is that the FGFR1 S789A stably transfected cells have evolved a compensatory mechanism to ensure endocytosis and accurate signaling from the receptor. It seems that mechanisms involved in regulating endocytosis such as ubiquitination might be redundant and interrelated. 31 One mechanism might be predominant under physiological conditions, whereas other mechanisms are used only when the main mechanism is inhibited experimentally or under pathological conditions. It is also possible that the stronger effect on FGFR1 endocytosis by RSK2 inhibition than mutation of S789 in FGFR1 is due to other substrates of RSK2 involved in the endocytic machinery.
It might seem somewhat contradictory that only phosphorylated RSK2 binds to FGFR1 in vivo while in the yeast two-hybrid screens, RSK2 was picked up as a binding partner for FGFR1 also in an unphosphorylated state. Full-length RSK2 appears in a closed, autoinhibited conformation that is opened upon phosphorylation by MAPKs. The domains in RSK2 interacting with FGFR1 in yeast two-hybrid screens consist of parts of the NTKD of RSK2 and not the full-length RSK2 (Figure 1a) . In the yeast two-hybrid screen, the unmasked NKTD can therefore readily bind FGFR1 without phosphorylation.
Only a few studies concerning FGFR signaling and RSKs have been published to date. In 2004, Pan et al. 32 reported that RSK1
BI-D1870 - can bind directly to KGFR (FGFR2 IIIb) and that expression of a dominant negative RSK1 construct reduced KGF-induced AKT activity. The RSK1 interaction site in KGFR was not identified in this study, and it would be interesting to investigate whether binding of RSK1 to KGFR is dependent on the serine in FGFR2 that corresponds to serine 789 in FGFR1. In 2007, Kang et al. 33 reported that active FGFR3 directly phosphorylates RSK2, regulating RSK2 activation by facilitating binding of inactive ERKs to RSK2. They also demonstrated that FGFR3-induced activation of RSK2 was required for survival of multiple myeloma cells expressing a constitutive active form of FGFR3. In 2009, Xian et al. 34 identified RSK2 as a critical component of FGFR1 signaling in lobular carcinomas. Inactivation of RSK activity induced cell-death of FGFR1-transformed cells, but not of the parental MCF10A cell line. These findings indicate the FGFR1-RSK2 signaling loop as a potential target in cancer therapy. However, as the present study suggests, inhibiting RSK2 activity could lead to delayed downregulation of FGFRs and could therefore lead to unwanted, excessive signaling through other pathways activated by FGFRs. Caution should therefore be exerted when designing therapies targeting the RSK2 axis in cancer.
MATERIALS AND METHODS
Antibodies and reagents
The following primary antibodies were used with the catalogue numbers indicated in parentheses: rabbit anti-FGFR1 (C19) (sc-121), goat anti-RSK2 (sc-1430), mouse anti-GST (sc-138), mouse anti-Ubiquitin (sc-8017), rabbit IgG (sc-66931), goat IgG (sc-34665) from Santa Cruz Biotechnology (Dallas, TX, USA); mouse anti-phospho-FGFR (Tyr653/Tyr654) (#3476), rabbit antiphospho-LKB1 (Ser428) (#3482), mouse anti-phospho-ERK1/2 (p44/p42) (Thr202/Tyr204) (#9106), rabbit anti-ERK1/2 (#9102) from Cell Signaling (Danvers, MA, USA); rabbit anti-FGFR1 (C-term) (2144-1) was from Epitomics (Burlingame, CA, USA); mouse anti-GAPDH-HRP (Ab9482) from Abcam (Cambridge, UK); rabbit anti-phospho-RSK (RSK1/RSK2 Ser221/Ser227) (AF892) from R&D Systems (Minneapolis, MN, USA); mouse anti-EEA1 from BD Transduction Laboratories (Franklin Lakes, NJ, USA). Rabbit anti-phospho-serine-789-FGFR1 antibody (p-S789-FGFR1) was made by GenScript (Piscataway, NJ, USA) using a synthetic phosphopeptide DTRSSTC(pS)SGEDSVF. The antibody was purified using the phosphopeptide and by cross-adsorption to the corresponding nonphosphopeptide. Rabbit anti-phospho-serine-777-FGFR1 antibody (p-S777-FGFR1) was also made by GenScript and is described in. 13 Secondary antibodies were from Jackson Immuno-Research Laboratories (West Grove, PA, USA).
Heparin Sepharose CL-6B affinity resin, Glutathione Sepharose resin and Quantum 333 medium were from GE Healthcare (Piscataway, NJ, USA). Protease inhibitor cocktail tablets (EDTA-free, complete) and DOTAP liposomal transfection reagent were from Roche Diagnostics (Basel, Switzerland). Dynabeads Protein G, Geneticin (G-418) and Hoechst 33342 were purchased from Life Technologies (Paisley, UK). RSK2 N-terminal kinase inhibitors, SL 0101-1 and BI-D1870 were from Tocris Bioscience (Bristol, UK) and Enzo Life Science (Farmingdale, NY, USA), respectively. [g- 33 P] ATP-3000 Ci/mmol, 10 mCi/ml and [ 125 I]Na were from PerkinElmer (Waltham, MA, USA). Iodination tubes and DyLight 549 were from Thermo Scientific Dharmacon (Rockford, IL, USA). Mowiol, Brefeldin A, PD173074, heparin, U0126, gelatin, Phosphatase inhibitor cocktail 2 and 3, a-cyano-4-hydroxycinnamic acid acetonitrile and trifluoroacetic acid were from Sigma-Aldrich (St Louis, MO, USA).
Cells
The human osteosarcoma cell line, U2OS, and the human normal foreskin fibroblast cell line, BJ, were from ATCC (Manassas, VA, USA). U2OS cells stably expressing FGFR1 (U2OS-R1) have been described previously. 15 DOTAP liposomal transfection reagent was used according to the manufacturer's protocol to obtain U2OS cells stably expressing S789A and S789D mutants of FGFR1. Clones were selected with 1 mg/ml geneticin (G-418). Clones were chosen based on their receptor expression levels analyzed by immunofluorescence and immunoblotting. The U2OS cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal bovine serum and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) in a 5% CO 2 atmosphere at 37 1C. In addition, 0.2-1 mg/ml geneticin was added to the growth media of the stably transfected U2OS cells. BJ cells were grown in Quantum 333 medium supplemented with antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin) in a 5% CO 2 atmosphere at 37 1C. Cells were seeded into tissue culture plates the day preceding the start of the experiments.
Plasmids and siRNA oligos pcDNA3-hFGFR1 has been described previously.
23 pcDNA3-hFGFR1 was used as a template for QuickChange (Agilent Technologies, SantaClara, CA, USA) site-directed mutagenesis to generate serine and threonine double and single mutants. All constructs were verified by sequencing. A construct encoding the last 68 C-terminal amino acids from FGFR1 (residues 755-822) in a pGEX vector was used for expression of FGFR1 C-tail fused to the C-terminus of GST. 20 siRNA oligos targeting RSK2 was purchased from Santa Cruz Biotechnology (sc-36441) and Ambion Life Technologies (Carlsbad, CA, USA). ON-TARGET plus non-targeting siRNA (scr) was from Thermo Scientific Dharmacon.
Cell transfection
Transient expression of the different constructs was performed by transfecting cells with plasmid DNA using Fugene 6 transfection reagent (Roche Diagnostics) according to the manufacturer's protocol. Cells were seeded into plates the day preceding the transfection and experiments were performed the following day.
siRNA knockdown was performed using Lipofectamine RNAiMAX Transfection Reagent (Life Technologies) according to the manufacturer's protocol. Experiments were performed 48-72 h after transfection. siRNA oligos targeting RSK2 from Santa Cruz Biotechnology and Ambion Life Technologies were combined to ensure efficient knockdown. ON-TARGET plus non-targeting siRNA (scr) was from Thermo Scientific Dharmacon.
Recombinant proteins and peptides
Active and inactive human recombinant RSK2 for in vitro phosphorylation assay were purchased from SignalChem (Richmond, ON, Canada) and Life Technologies, respectively. Recombinant FGF1 was produced as described previously. 35 FGF2 was a generous gift from Michal Kostas, Faculty of Biotechnology, University of Wroclaw, Poland. Recombinant EGF was obtained from Sigma-Aldrich. Recombinant fusion protein of the C-terminus part of FGFR1 with GST (GST tagged C-tail-FGFR1) and the 
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Active RSK2 Figure 9 . Schematic presentation of the RSK2 mediated feedback loop in FGFR1 signaling. Binding of FGF1 to the extracellular part of FGFR1 leads to autophosphorylation of 7 tyrosine residues in the intracellular part of FGFR1 (pTyr) and activation of downstream signaling pathways such as the ERK1/2 pathway. ERK1/2 can then directly phosphorylate FGFR1 on serine 777 (S777) leading to attenuation of FGFR1 phospho-tyrosine signaling. In addition, ERK1/ 2 activates its downstream signaling target, RSK2, which in turn can bind to and phosphorylate FGFR1 on serine 789 (S789). Binding of FGF1 to FGFR1 also induces FGFR1 endocytosis. If RSK2 activity is blocked (panel to the right), serine 789 in FGFR1 is not longer phosphorylated, and the endocytosis of FGFR1 is severely reduced. Blockage of RSK2 activity does not interfere with ERK1/2-mediated phosphorylation of S777 in FGFR1.
